Redeye updates its estimates and valuation following Mentice’s Q1 2024 report. Both top-line and profitability figures came in far below our estimates. However, we judge that investors should not extrapolate the quarter into the future, given the substantial q/q volatility of Mentice’s net sales and order intake. We lower our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/